Owens & Minor
This article was originally published in The Gray Sheet
Executive Summary
Completes merger with Stuart Medical following shareholder approval on May 10. The Justice Department in February finished its antitrust review of the transaction, which was announced in December ("The Gray Sheet" Feb. 14, In Brief). Corporate management changes announced at the May 10 shareholder meeting include: G. Gilmer Minor, III named chairman, replacing G. Gilmer Minor, Jr., who becomes chairman emeritus; Carl Grefenstette, chair and CEO of the Hillman company, which previously owned most of Stuart Medical, joins O&M board; and former Stuart President and CEO Richard Byington becomes O&M executive vice president. Also promoted to executive VP are O&M's Robert Anderson, Henry Berling and Craig Smith. Thomas Sherry, formerly with Stuart, becomes Owens & Minor's VP, sales and marketing
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.